US2016272726A1PendingUtilityA1

Prevention and treatment of complement-associated eye conditions

55
Assignee: GENENTECH INCPriority: May 23, 2007Filed: Feb 3, 2016Published: Sep 22, 2016
Est. expiryMay 23, 2027(~0.8 yrs left)· nominal 20-yr term from priority
Inventors:Philip E. HassYin JianpingKenneth KatschkeMicah SteffekChristian WeismannMenno Van Lookeren Campagne
A61P 9/14A61P 37/00A61P 9/10A61P 43/00A61P 27/00A61P 27/02A61P 3/10A61P 27/10A61P 31/04C07K 2317/56C07K 2317/24A61K 39/3955A61K 2039/505Y10S435/975C07K 16/40A61K 9/0048C07K 2317/565A61K 45/00C12N 9/64C07K 2317/20A61K 39/395
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for the prevention or treatment of a complement-associated eye condition comprising administering to a subject in need an effective amount of a Factor D antagonist. 
     
     
         2 . The method of  claim 1  wherein said subject is a mammal. 
     
     
         3 . The method of  claim 2  wherein said subject is a human. 
     
     
         4 . The method of  claim 3  wherein said Factor D antagonist is selected from the group consisting of anti-Factor D antibodies and fragments thereof, binding polypeptides, peptides, and non-peptide small molecules. 
     
     
         5 . The method of  claim 4  wherein said Factor D antagonist is an antibody or an antibody fragment. 
     
     
         6 . The method of  claim 5  wherein said antibody binds to the active site of Factor D. 
     
     
         7 . The method of  claim 5  wherein said antibody binds to an epitope including active site residues of Factor D. 
     
     
         8 . The method of  claim 5  wherein said antibody is selected from the group consisting of antibodies 20D12, 31A9, 25A1 and 32H12, and variants thereof. 
     
     
         9 . The method of  claim 5  wherein said antibody bind essentially to the same epitope as antibody 20D12. 
     
     
         10 . The method of  claim 5  wherein said antibody comprises the heavy and/or light chain CDR sequences of antibody 20D12 (SEQ ID NOS: 1 and 2). 
     
     
         11 . The method of  claim 5  which is a human, humanized or chimeric antibody. 
     
     
         12 . The method of  claim 5  wherein said antibody fragment is selected from the group consisting of Fab, Fab′, F(ab′) 2 , scFv, (scFv) 2 , dAb, complementarity determining region (CDR) fragments, linear antibodies, single-chain antibody molecules, minibodies, diabodies, and multispecific antibodies formed from antibody fragments. 
     
     
         13 . The method of  claim 12  wherein said antibody fragment is a Fab, Fab′, F(ab′) 2 , scFv, or (scFv) 2  fragment. 
     
     
         14 . The method of  claim 3  wherein said complement-associated eye condition is selected from the group consisting of age-related macular degeneration (AMD), choroidal neovascularization (CNV), uveitis, diabetic and other ischemia-related retinopathies, diabetic macular edema, pathological myopia, von Hippel-Lindau disease, histoplasmosis of the eye, Central Retinal Vein Occlusion (CRVO), corneal neovascularization, and retinal neovascularization. 
     
     
         15 . The method of  claim 14  wherein said AMD is dry AMD. 
     
     
         16 . The method of  claim 14  wherein said AMD is wet AMD. 
     
     
         17 . A kit comprising a Factor D antagonist and instructions for administering said antagonist to treat a complement-associated eye condition. 
     
     
         18 . The kit of  claim 17  wherein said complement-associated eye condition is selected from the group consisting of age-related macular degeneration (AMD), choroidal neovascularization (CNV), uveitis, diabetic and other ischemia-related retinopathies, diabetic macular edema, pathological myopia, von Hippel-Lindau disease, histoplasmosis of the eye, Central Retinal Vein Occlusion (CRVO), corneal neovascularization, and retinal neovascularization. 
     
     
         19 . The kit of  claim 18  wherein said complement-associated eye condition is AMD or CNV. 
     
     
         20 . The use of a Factor D antagonist in the preparation of a medicament for the treatment of a complement-associated eye condition. 
     
     
         21 . A Factor D antagonist for use in the treatment of a complement-associated eye condition.

Join the waitlist — get patent alerts

Track US2016272726A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.